Addressing Current Questions and Controversies in the Management of Non-Small Cell Lung Cancer with an EGFR Mutation (Webinar Audio Proceedings)
Addressing Current Questions and Controversies in the Management of Non-Small Cell Lung Cancer with an EGFR Mutation (Webinar Audio Proceedings) is organized by Research To Practice (RTP).
Release Date: November 2020
Expiration Date: November 2021
Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio)
• Recognize the spectrum of oncogenic alterations identifiable in the epidermal growth factor receptor (EGFR) tyrosine kinase domain, and determine how they may predict potential response or lack thereof to EGFR-directed therapy.
• Appreciate emerging Phase III findings supporting the use of adjuvant osimertinib after complete resection for patients with non-small cell lung cancer (NSCLC) with EGFR mutations, and consider the potential effect of this information on clinical practice.
• Evaluate available clinical trial findings supporting the use of osimertinib as first-line therapy for patients with NSCLC with EGFR mutations, and consider the effect of this information on current and future clinical practice.
• Comprehend the mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and discern how available and investigational therapies can be optimally employed in protocol and nonresearch care of patients with progressive NSCLC with EGFR mutations.
• Formulate an optimal approach to the clinical care of patients with NSCLC with EGFR mutations and CNS metastases, considering the implications of symptomatology, number of lesions and other factors.
• Consider available research data to determine how to sequence immune checkpoint inhibitors in the long-term care of patients with metastatic NSCLC and an EGFR activating mutation.
• Understand the biologic rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches for patients with NSCLC and EGFR mutations.
End of life care
- CME : 1.75
- MOC : 1.75
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).
Number of Health Care Professionals Registered: 0 Number
Toll free Number
Browse CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine